%0 Journal Article %T Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice %A Aldo V Giordano %A Alessandro Parisi %A Alessio Cortellini %A Antonella Dal Mas %A Antonio Marchetti %A Antonio Russo %A Carla DĄŻOrazio %A Corrado Ficorella %A Fiamma Buttitta %A Giuseppe Calvisi %A Katia Cannita %A Lara Felicioni %A Olga Venditti %A Paola Lanfiuti Baldi %A Roberto Vicentini %A Vincenzo Vicentini %J Archive of "OncoTargets and therapy". %D 2019 %R 10.2147/OTT.S194745 %X Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety %K metastatic colorectal cancer %K intensive chemotherapy regimen %K bevacizumab %K clinical practice %K 5-fluorouracil infusion %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438145/